Vaccinex will deliver a symposium presentation and poster presentation during the upcoming AD/PD 2025 International Conference which will take place in Vienna, Austria and online April 1-5. For more info and to register, visit: https://bit.ly/3QNXhtf #ADPD2025
Vaccinex
生物技术研究
Rochester，New York 1,789 位关注者
Pioneering a differentiated approach to treating cancer & neurodegenerative diseases.
关于我们
Vaccinex (NASDAQ: VCNX) is a clinical stage biotechnology company pioneering a differentiated approach to treating cancer and progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers damaging inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer’s Disease, with ongoing exploration of potential Phase 3 development in Huntington’s disease. The Company has also developed a proprietary drug discovery platform, ActivMAb?, that it is leveraging thru strategic collaborations, particularly by exploiting its unique capability to select high value antibodies against important multi-pass membrane receptors.
- 网站
-
https://www.vaccinex.com/
Vaccinex的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Rochester，New York
- 类型
- 上市公司
地点
-
主要
获取路线
1895 Mt Hope Ave
US，New York，Rochester，14620
Vaccinex员工
-
John Leonard
Consultant,Technical Operations, Retired Sr Vice President; Vaccinex, Inc
-
Terry Fisher
Sr. Vice President, Clinical Development at Vaccinex, Inc.
-
Barbara Yanni
Independent Director of Public and Private Biotechnology Companies. Former VP and Chief Licensing Officer of Merck.
-
Renee Kirk
Senior Research Scientist at Vaccinex, Inc
动态
-
SEMA4D is a biological effector that is believed to induce myeloid suppression and immune evasion in tumors and trigger neuroinflammation. Vaccinex's clinical programs are focused on inhibiting SEMA4D to potentially address various neurological diseases and cancers. https://bit.ly/2O4G4yP
-
Vaccinex’s proprietary ActivMAb? Technology enables expression of functional, properly folded complex proteins such as GPCRs and Ion Channels on the relatively simple membrane of poxvirus providing an efficient source of antigen for various antibody discovery strategies. Learn more: https://bit.ly/2WtsTsg
-
We look forward to attending this year's AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders which will be held in Vienna, Austria and online on April 1-5. Learn more here: https://bit.ly/3QNXhtf #ADPD2025
-
Vaccinex's antigen-expressing virions enable antibody discovery on complex antigens using methods that are utilized for simple purified proteins. Learn more and see our full catalogue here: https://bit.ly/2WtsTsg
-
-
Alzheimer's disease is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Learn more about Alzheimer's from Alzheimer's Association?: https://bit.ly/3ILh3BK
Alzheimer's Association 2024 Alzheimer's Disease Facts and Figures
https://www.youtube.com/
-
Pepinemab, in combination with a checkpoint inhibitor, has been found to significantly enhance T-cell infiltration and to simultaneously reduce immunosuppressive cells in tumors, a potentially powerful combination to increase anti-tumor activity. Learn more: https://bit.ly/3fA7hEn
-
Vaccinex’s proprietary ActivMAb? Technology enables expression of functional, properly folded complex proteins such as GPCRs and Ion Channels on the relatively simple membrane of poxvirus providing a source of antigen for various antibody discovery strategies. Learn more: https://bit.ly/3tbCTKe
-
-
Our lead drug candidate, pepinemab, blocks SEMA4D and has potential to improve both immune activity against tumors & the underlying pathogenic immune mechanisms that amplify damage in chronic neurological disorders such as Alzheimer’s and Huntington’s disease. More info: https://bit.ly/3nN9ltS